[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2000005263A3 - Compounds for use in the treatment of inflammation - Google Patents

Compounds for use in the treatment of inflammation Download PDF

Info

Publication number
WO2000005263A3
WO2000005263A3 PCT/GB1999/002392 GB9902392W WO0005263A3 WO 2000005263 A3 WO2000005263 A3 WO 2000005263A3 GB 9902392 W GB9902392 W GB 9902392W WO 0005263 A3 WO0005263 A3 WO 0005263A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
inhibition
manufacture
compound
inflammation
Prior art date
Application number
PCT/GB1999/002392
Other languages
French (fr)
Other versions
WO2000005263A2 (en
Inventor
Mauro Perretti
Stephen Getting
Roderick Flower
Original Assignee
William Harvey Research Limite
Mauro Perretti
Stephen Getting
Roderick Flower
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Harvey Research Limite, Mauro Perretti, Stephen Getting, Roderick Flower filed Critical William Harvey Research Limite
Priority to AU50560/99A priority Critical patent/AU5056099A/en
Publication of WO2000005263A2 publication Critical patent/WO2000005263A2/en
Publication of WO2000005263A3 publication Critical patent/WO2000005263A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/69—Beta-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Use of a compound comprising an amino acid sequence HFRW in the manufacture of a medicament for inhibition of neutrophil chemoattractant production, inhibition of polymorphonuclear cell (PMN) accumulation, or reduction/treatment of inflammatory response/disease, and/or in the manufacture of an agonist of melanocortin receptor type 3 (MC3-R); wherein the compound is not adrenocorticotrophic hormone (ACTH)1-39 or a fragment thereof which activates the production of glucocorticoids.
PCT/GB1999/002392 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation WO2000005263A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50560/99A AU5056099A (en) 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816234.0A GB9816234D0 (en) 1998-07-24 1998-07-24 Compounds for use in the treatment of inflammation
GB9816234.0 1998-07-24

Publications (2)

Publication Number Publication Date
WO2000005263A2 WO2000005263A2 (en) 2000-02-03
WO2000005263A3 true WO2000005263A3 (en) 2000-05-04

Family

ID=10836177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002392 WO2000005263A2 (en) 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation

Country Status (3)

Country Link
AU (1) AU5056099A (en)
GB (1) GB9816234D0 (en)
WO (1) WO2000005263A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
IL159797A0 (en) 2001-07-11 2004-06-20 Palatin Technologies Inc Linear and cyclic melanocortin receptor-specific peptides
EP1529535A1 (en) * 2003-11-06 2005-05-11 IPF PharmaCeuticals GmbH Isolation of a circulating human lipolytic peptide
CN1909930B (en) 2004-01-21 2015-12-16 诺和诺德医疗保健公司 The joint of transglutaminase mediated peptide
US20100204113A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of stresscopin-related peptide as a therapeutic agent
WO2009046861A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent
CA2727317C (en) 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
AU2010259008C1 (en) 2009-06-08 2016-04-21 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
MX2012005862A (en) 2009-11-23 2012-09-07 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides.
CA2781405A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
CN110585215B (en) * 2019-09-19 2023-06-02 中山大学 New application of hemin and its complex in medicine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146113A2 (en) * 1983-12-15 1985-06-26 Dieter Aderhold Active agent and therapeutical composition for the treatment of deincephalon failures of nervous deseases and skin diseases
FR2691465A1 (en) * 1992-05-25 1993-11-26 Pf Medicament New melanotropin peptide(s) and polysaccharide conjugates - useful as antiinflammatory, antiallergic, immunosuppressant and skin-tanning agents
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146113A2 (en) * 1983-12-15 1985-06-26 Dieter Aderhold Active agent and therapeutical composition for the treatment of deincephalon failures of nervous deseases and skin diseases
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
FR2691465A1 (en) * 1992-05-25 1993-11-26 Pf Medicament New melanotropin peptide(s) and polysaccharide conjugates - useful as antiinflammatory, antiallergic, immunosuppressant and skin-tanning agents
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HILTZ M E ET AL: "ALPHA-MSH PEPTIDES INHIBIT ACUTE INFLAMMATION AND CONTACT SENSITIVITY", PEPTIDES,US,ELMSFORD, vol. 11, no. 5, 1 January 1990 (1990-01-01), pages 979 - 982, XP000644695, ISSN: 0196-9781 *
JAYAWICKREME E A: "Discovery and structure-function analysis of alpha-MSH antagonists", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 269, no. 47, 25 November 1994 (1994-11-25), pages 29846 - 29854-29854, XP002112308, ISSN: 0021-9258 *
PENG E A: "Binding and biological activity of C-terminally modified melanocortin peptides", PEPTIDES,US,ELMSFORD, vol. 18, no. 7, 1997, pages 1001 - 1008-1008, XP002113015, ISSN: 0196-9781 *
SCHIÖTH E A: "Selectivity of cyclic [D-Nal-7] and [D-Phe-7] substituted MSH analogues for the melanocortin receptor substypes", PEPTIDES,US,ELMSFORD, vol. 18, no. 7, 1997, pages 1009 - 1013-1013, XP002113070, ISSN: 0196-9781 *

Also Published As

Publication number Publication date
WO2000005263A2 (en) 2000-02-03
AU5056099A (en) 2000-02-14
GB9816234D0 (en) 1998-09-23

Similar Documents

Publication Publication Date Title
WO2000005263A3 (en) Compounds for use in the treatment of inflammation
AU5090099A (en) Salts and bases of the 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
CA2321728A1 (en) Epiallopregnanolone in the treatment of cns disorders
WO1999062908A3 (en) Cell adhesion-inhibiting antinflammatory compounds
CA2333938A1 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
BR9916746A (en) Antiinflammatory compounds that inhibit cell adhesion
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
CA2262692A1 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
CA2338220A1 (en) Substituted imidazoles having cytokine inhibitory activity
CA2419517A1 (en) Wide slit nozzle and coating method by wide slit nozzle
CY2009010I1 (en) METHOD FOR ENRICHMENT OF R-EPIMER OF 16,17-ACETAL DERIVATIVES OF 21-ACYLOXY PREGNA-1,4-DIEN-11.BETA., 16.ALPHA., 17.ALPHA.-TRIOL-3,20-DIONE
EP1574219A3 (en) Method of inhibiting fibrosis with a somatostatin agonist
BR9907788A (en) Paraglycocorticoid selective anti-inflammatory agents
CA2362281A1 (en) Combinations for the treatment of diseases involving angiogenesis
AU6281599A (en) Alternate day administration of copolymer 1 for treating autoimmune diseases
HK1022419A1 (en) Agent for inhibition of cytokine production and agent for inhibition of cell adhesion.
PL327831A1 (en) Application of 3,4-diphenylchromanes in production of a pharmaceutic agent for treating or preventing menopause symptoms
WO1994000555A3 (en) Compositions for the inhibition of protein hormone formation and uses thereof
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
AU7689996A (en) Cortisone spray for topical administration
EP1275379A3 (en) Basic granulate comprising (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
MY114428A (en) New pharmacological use of aii-receptor antagonists
AU5160599A (en) Method for the production of n,n'-carbonyl diazoles
WO1998014454A3 (en) (o-ACYL-p-N-ACYLAMINO-PHENYL)-O-PHOSPHOETHANOLAMINES
WO2000076457A3 (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase